FilingsTodayCellromax Science
At a glance
Cellromax Science filed 42 disclosures in the last 12 months, including 5 insider, 4 buyback and 3 5% holder. The most recent key filing was on Apr 20.
Revenue for 2025 was ₩22.2B, up 2.6% on 2024. Operating margin was 12.8% against 25.4% a year earlier. Debt was 9% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩9.8B and operating profit of ₩1.3B.
The 2025 annual report lists 52 employees with an average tenure of 2.7 years and average pay of ₩43.8M, #1677 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩160M each on average. It paid ₩185 per common share in cash dividends, against ₩165 a year earlier (+12.1%). 서정민 and related parties held 69.50% at year end.
From the 2025 annual report
Staff: 52 (16 men, 36 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩2.1B. Directors and auditors: 6, paid ₩957M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩185 | ₩165 | - |
| Payout ratio | 69.9% | 49.1% | - |
| Yield (as filed) | 3.50% | 3.10% | - |
| Total cash dividends | ₩2.1B | ₩1.9B | - |
Largest shareholder
서정민 holds 35.49%; with 6 related parties the group holds 69.50% of common shares at year end (from 68.49% at the start of the year).
Auditor: 정인회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.